Coley Pharmaceutical Group Initiates Phase I Clinical Trials of Actilon(TM) for
- Coley Pharmaceutical Group Initiates Phase I Clinical Trials of Actilon(TM) for Chronic Hepatitis C Infection
Tuesday January 13, 8:33 am ET
Third Coley TLR9 Agonist Product to Advance into Clinic
WELLESLEY, Mass., Jan. 13 /PRNewswire/ -- Coley Pharmaceutical Group, Inc. today announced the initiation of Phase I clinical studies of Actilon(TM) (CPG 10101), a novel synthetic TLR9 agonist, targeted for patients with chronic hepatitis C infection (HCV).
[Non-text portions of this message have been removed]